Search Results - "Biesel, E."

Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer by Hipp, J, Hussung, S, Timme-Bronsert, S, Boerries, M, Biesel, E, Fichtner-Feigl, S, Fritsch, R, Wittel, U A

Get full text

High serum CA19–9 preoperatively reduces POPF risk after pancreatoduodenectomy in PDAC by Chikhladze, S., Hipp, J., Biesel, E., Weckler, M., Ruess, D.A., Kousoulas, L., Hopt, U., Fichtner-Feigl, S., Wittel, U.A.

“…Recent groundbreaking work revealed CA19–9 is not only a tumor marker for PDAC. It also induces severe pancreatitis and promotes pancreatic fibrosis. The aim…”
Get full text

Prediction Model for Severe Morbidity and Diabetes Type III after Central Pancreatectomy: Patient Selection in an International Retrospective Multicenter Study by van Bodegraven, E.A., Lof, S., Jones, L., Aussilhou, B., Yong, G., Jishu, W., Klotz, R., Rocha-Castellanos, D.M., Matsumato, I., de Ponthaud, C., Tanaka, K., Biesel, E., Kauffmann, E., Dumitrascu, T., Nagakawa, Y., Martí-Cruchaga, P., Roeyen, G., Zerbi, A., Goetz, M., de Meijer, V., Pessaux, P., Ignatavicius, P., Demir, I., Giuffrida, M., Tingstedt, B., Marino, M.V., Mastoridis, S., Brunner, M., Mora-Oliver, I., Bortolato, C., Gulla, A., Apers, T., Hermand, H., Mitsuka, Y., Popescu, I., Boggi, U., Wittel, U., Hirano, S., Gaujoux, S., Kamei, K., Fernández-Del Castillo, C., Hackert, T., Kuirong, J., Yi, M., Sauvanet, A.

Get full text

Clinical characteristics and long-term outcomes following pancreatic injury – An international multicenter cohort study by Meijer, Laura L., Vaalavuo, Yrjö, Regnér, Sara, Sallinen, Ville, Lemma, Aurora, Arnelo, Urban, Valente, Roberto, Westermark, Sofia, An, David, Moir, John A.G., Irwin, Ellen A., Biesel, Esther A., Hopt, Ulrich T., Fichtner-Feigl, Stefan, Wittel, Uwe A., Weniger, Maximilian, Karle, Henning, Bloemers, Frank W., Sutton, Robert, Charnley, Richard M., Ruess, Dietrich A., Szatmary, Peter

“…Trauma to the pancreas is rare but associated with significant morbidity. Currently available management guidelines are based on low-quality evidence and data…”
Get full text

Tolerance of Haemofusin in hemodilution and volume substitution by Kaniecki, K, Biesel, E, Zielke, E

“…In an open and uncontrolled trial the frequency and the type of adverse events were registered in patients who received Haemofusin, a hydroxyethyl starch…”
Get more information